莎普爱思(603168.SH)获得去氧肾上腺素酮咯酸溶液临床试验批准通知书

Core Viewpoint - The company, Shapuaisi (603168.SH), has received approval from the National Medical Products Administration for clinical trials of deoxycorticosterone ketone acid solution, which is intended for use during cataract surgery to maintain pupil dilation and alleviate postoperative eye pain [1] Group 1 - The company plans to conduct clinical trials once conditions are met [1] - The drug is primarily used to prevent pupil constriction during cataract surgery or artificial lens replacement [1] - As of the announcement date, the total R&D investment in the deoxycorticosterone ketone acid solution project is approximately 5.5563 million RMB [1]